Skip to main content
Explore URMC
menu

Richard G. Moore, M.D.

Contact Information

Phone Numbers

Appointment: (585) 442-8020

Administrative: (585) 442-8020

Office: (585) 442-8020

Fax: (585) 442-8039

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Settings

Cancer, Obstetrics & Gynecology

Biography

I believe all patients should be treated with compassion, along with an individualized plan for their treatment and care utilizing a multidisciplinary team approach. We approach each of our patients with the philosophy of "What would you want done for your loved one?" (Quote from Cornelius "Skip" Granai, III, M.D.)

Gynecologic oncology is a unique subspecialty that provides for the participation in all parts of a patient's care. The opportunity to be involved in such a personal experience during a patient's life -- from the time of diagnosis through surgery to managing chemotherapy and participating in all aspects of a woman's care -- is an honor and privilege.

My areas of expertise include robotic surgery for ovarian, endometrial and cervical malignancies, as well as sentinel lymph node mapping for endometrial, cervical and vulvar malignancies, and ovarian cancer biomarker research for the early detection and management of ovarian cancer.

Conditions I Treat:

- Ovarian cancer
- Fallopian tube cancer
- Primary peritoneal cancer
- Endometrial cancer
- Cervical cancer
- Vaginal cancer
- Vulvar cancer

Professional Background

Richard G. Moore, M.D., FACOG, FACS, joined UR Medicine's Obstetrics and Gynecology as the Director of the Gynecologic Oncology Division on October 1, 2015. Dr. Moore will also lead Wilmot Cancer Institute's Gynecology Service Line and serve as Director of the Targeted Therapeutics Laboratory for Gynecologic Cancers.

Dr. Moore comes to UR Medicine from Brown University and Women & Infants Hospital of Rhode Island. A native of Montreal, Quebec, Canada, Dr. Moore graduated from the University of Alberta Medical School in Edmonton. He completed his residency at Eastern Virginia Graduate School of Medicine, where he also served as Administrative Chief Resident. He completed a fellowship in Gynecologic Oncology and Breast Surgery at Women & Infants Hospital/Brown University. Dr. Moore joined the faculty at Women and Infants/Brown University after leaving fellowship. He served as the Associate Director of the Program in Women's Oncology since 2009 and was the Director of the Center for Biomarkers and Emerging Technology as well as the Molecular Therapeutics laboratory.
Dr. Moore is board-certified in gynecologic oncology and is a fellow of the American College of Obstetricians and Gynecologists and a fellow of the American College of Surgeons.
In addition to his clinical interest in ovarian and endometrial cancers, Dr. Moore is recognized internationally as a leading expert on the use of biomarkers to detect ovarian cancer. He led the team that developed the Risk of Ovarian Malignancy Algorithm (ROMA), a test that is cleared for use in Europe and Asia and was recently cleared by the U.S. Food and Drug Administration to detect ovarian cancer in women who have an ovarian cyst or pelvic mass.
Dr. Moore will see patients at 125 Lattimore Road, Suite 258 and will perform surgeries at Highland Hospital, which has been awarded the Gold Seal of Approval by the Joint Commission and leads the state in the number of minimally invasive, robotic surgeries for gynecologic cancer performed each year.

Credentials

Specialties

  • Gynecologic Oncology - American Board of Obstetrics and Gynecology
  • Obstetrics and Gynecology - American Board of Obstetrics and Gynecology

Education

1993
MD | University of Alberta

Post-doctoral Training & Residency

07/01/1999 - 06/30/2002
Fellowship in Gynecologic Oncology at Brown University Program in Medicine

07/01/1994 - 06/30/1997
Residency in Obstetrics and Gynecology at Eastern Virginia Medical School of the Medical Col

07/01/1993 - 06/30/1994
Internship in Obstetrics and Gynecology at Eastern Virginia Medical School of the Medical Col

VIEW ALL expand_more

Awards

2015
Consumer's Research Council of America
Sponsor: Guide to America's Top Obstetricians and Gynecologists

2014 - 2014
New England Association of Gynecologic Oncologists
Sponsor: Basic Science Paper Award. Mentee: Elizabeth Lokich, MD. HE4 ex
Location: Newport RI,

2014
Rhode Island Monthly Journal, 2014
Sponsor: Rhode Island Top Doc

2013
AACC's Outstanding Speaker Award for 2013
Sponsor: American Association of clinical Chemists

2013
Consumer's Research Council of America
Sponsor: Guide to America's Top Obstetricians and Gynecologists

2013
Rhode Island Monthly Journal, 2013
Sponsor: Rhode Island Top Doc

2012
Rhode Island Monthly Journal, 2012
Sponsor: Rhode Island Top Doc

2012
Consumer's Research Council of America
Sponsor: Guide to America's Top Obstetricians and Gynecologists

2011
Providence Business News Innovation Awards 2011
Sponsor: For the "Artificial Ovary
Location: Brown University and Women and Infants Hospital

2011
Consumer's Research Council of America
Sponsor: Guide to America's Top Obstetricians and Gynecologists

2010
Time Magazine: Top ten Medical Breakthroughs for 2010
Sponsor: In vitro maturation of oocytes via the prefabricated self-assem

2008
New England Association of Gynecologic Oncologists
Sponsor: Comparison of a novel multiple biomarker assay to the risk of ma
Location: Cape Cod

2008
New England Association of Gynecologic Oncologists
Sponsor: Differential expression of CA125 and a novel serum tumor marker
Location: Cape Cod

2008
Full Time Faculty Excellence in Teaching Award

2008
Teaching Award from Chief Residents: Full Time Faculty

2007 - 2007
SGO Clinical Practice Science Poster Award
Sponsor: sentinel lymph node dissection alone with conservative ...
Location: San Diego, CA

2006
Medical Student Teaching Award
Sponsor: BioMed 351
Location: Brown University

2006
2006 Outstanding faculty mentorship award; from the resident graduating class of 2006

2005
New England Association of Gynecologic Oncology
Sponsor: Long term follow-up of patients with stage I and II vulvar ...

2002
New England Association of Gynecologic Oncologists
Sponsor: Sentinel node identification and the ability to detect ...

1997
The American Association of Gynecologic Laparoscopists Award

1996 - 1997
Resident of the Year

1996 - 1997
Administrative Chief Resident

1996
Gynecologic Oncology Resident Award

1996
Society of Assisted Reproductive Medicine Award

VIEW ALL expand_more

Clinical Trials

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women With Recurrent, Persistent or Metastatic Endometrial Cancer (NRG-GY012)

Lead Researcher: Richard G Moore

This phase II trial studies the effects of the combination of olaparib and durvalumab, cediranib and durvalumab, olaparib and capivasertib, and cediranib alone in treating patients with endometrial cancer that has come back (recurrent) or does not respond to treatment (refractory). Olaparib, cediranib, and capivasertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Testing the combinations may lower the chance of endometrial cancer growing or spreading compared to usual care.

View Study Details

A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer

Lead Researcher: Richard G Moore

This phase III trial compares whether the addition of pembrolizumab to radiation therapy is more effective than radiation therapy alone in reducing the risk of cancer coming back (recurrence) in patients with newly diagnosed stage I-II endometrial cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. The addition of pembrolizumab to radiation treatment may be more effective than radiation treatment alone in reducing cancer recurrence.

View Study Details

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

Lead Researcher: Richard G Moore

This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back (recurrent). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Paclitaxel and carboplatin are chemotherapy drugs used as part of the usual treatment approach for this type of cancer. This study aims to assess if adding immunotherapy to these drugs is better or worse than the usual approach for treatment of this cancer.

View Study Details

A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]

Lead Researcher: Richard G Moore

This trial studies how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for women with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.

View Study Details

CGYO18021: Testing the addition of the antibody, atezolizumab, to chemotherapy with liposomal doxorubicin and bevacizumab in recurrent ovarian cancer

Lead Researcher: Richard G Moore

This phase II/III trial studies how well pegylated liposomal doxorubicin hydrochloride with atezolizumab and/or bevacizumab work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent). Chemotherapy drugs, such as pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. It is not yet known which combination will work better in treating patients with ovarian, fallopian tube, or primary peritoneal cancer.

View Study Details

NRG-GY019: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

Lead Researcher: Richard G Moore

This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of estrogen made by the body which in turn may stop the growth of tumor cells that need estrogen to grow. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving letrozole alone or in combination with paclitaxel and carboplatin works better in treating patients with low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum compared to paclitaxel and carboplatin without letrozole.

View Study Details

EMBER2 Study: Evaluation of multiple biomarkers to estimate risk of cancer in gynecology patients presenting with a pelvic mass (ANG-006)

Lead Researcher: Richard G Moore

The purpose of this study is to validate and refine a technology that can help physicians determine whether an abnormal pelvic mass in women is benign (non-cancerous) or malignant (cancerous) using a blood test. The specific technology is called ParsortixTM PC1 system, a semi-automated system capable of capturing and harvesting rare cells for subsequent analysis from blood based on the size and deformability of the cells.

View Study Details

A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer

Lead Researcher: Richard G Moore

This randomized phase III trial studies radiation therapy and cisplatin with triapine to see how well they work compared to the standard radiation therapy and cisplatin alone in treating patients with newly diagnosed stage IB2, II, or IIIB-IVA cervical cancer or stage II-IVA vaginal cancer. Radiation therapy uses high energy protons to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy and cisplatin are more effective with triapine in treating cervical or vaginal cancer.

View Study Details

UGYO17017: Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women

Lead Researcher: Richard G Moore

The goal of this clinical research study is to evaluate a method involving a blood test, called CA-125, that may be helpful in the early detection of ovarian cancer in women who are at low risk.

View Study Details

Patents

Patent Title: Therapy for Malignant Disease
Patent #: 10,376,535
Issue Date: Aug 13, 2019
Country: United States
Invented By: Richard G Moore, Rakesh K Singh, Naohiro Yano

Patent Title: Septin Proteins as Novel Biomarkers for Detection and Treatment of Mullerian Cancers
Patent #: 3311165
Issue Date: Dec 09, 2020
Country: Europe
Invented By: Richard G Moore, Rakesh K Singh

Patent Title: Septin Proteins as Novel Biomarkers for Detection and Treatment of Mullerian Cancers
Patent #: FR3311165
Issue Date: Dec 09, 2020
Country: France
Invented By: Richard G Moore, Rakesh K Singh

Patent Title: Septin Proteins as Novel Biomarkers for Detection and Treatment of Mullerian Cancers
Patent #: DE3311165
Issue Date: Dec 09, 2020
Country: Germany
Invented By: Richard G Moore, Rakesh K Singh

Patent Title: Septin Proteins as Novel Biomarkers for Detection and Treatment of Mullerian Cancers
Patent #: GB3311165
Issue Date: Dec 09, 2020
Country: United Kingdom
Invented By: Richard G Moore, Rakesh K Singh

Patent Title: Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
Patent #: 11,034,719
Issue Date: Jun 15, 2021
Country: United States
Invented By: Richard G Moore, Rakesh K Singh

Patent Title: Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
Patent #: 3128996
Issue Date: Jun 02, 2021
Country: Europe
Invented By: Richard G Moore, Rakesh K Singh

Patent Title: Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
Patent #: FR3128996
Issue Date: Jun 02, 2021
Country: France
Invented By: Richard G Moore, Rakesh K Singh

Patent Title: Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
Patent #: DE3128996
Issue Date: Jun 02, 2021
Country: Germany
Invented By: Richard G Moore, Rakesh K Singh

Patent Title: Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
Patent #: GB3128996
Issue Date: Jun 02, 2021
Country: United Kingdom
Invented By: Richard G Moore, Rakesh K Singh

Patent Title: Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
Patent #: 9,982,010
Issue Date: May 29, 2018
Country: United States
Invented By: Richard G Moore, Rakesh K Singh

Patent Title: 7-Dehydrocholesterol Derivatives and Methods Using Same
Patent #: 10,683,324
Issue Date: Jun 16, 2020
Country: United States
Invented By: Richard G Moore, Rakesh K Singh

VIEW ALL expand_more

Publications

Journal Articles

5/22/2020
James NE, Emerson JB, Borgstadt AD, Beffa L, Oliver MT, Hovanesian V, Urh A, Singh RK, Rowswell-Turner R, DiSilvestro PA, Ou J, Moore RG, Ribeiro JR. "The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genes." Scientific reports.. 2020 May 22; 10(1):8558. Epub 2020 May 22.

2/24/2020
Kim KK, Singh RK, Khazan N, Kodza A, Singh NA, Jones A, Sivagnanalingam U, Towner M, Itamochi H, Turner R, Moore RG. "Development of Potent Forchlorfenuron Analogs and Their Cytotoxic Effect in Cancer Cell Lines." Scientific reports.. 2020 Feb 24; 10(1):3241. Epub 2020 Feb 24.

2020
Kim KK, Turner R, Khazan N, Kodza A, Jones A, Singh RK, Moore RG. "Role of trypsin and protease-activated receptor-2 in ovarian cancer." PloS one.. 2020 15(5):e0232253. Epub 2020 May 04.

Books & Chapters

2011
Chapter Title: Breast Development and Anatomy
Book Title: Clinical Obstetrics and Gynecology
Author List: Sonali Pandya and Richard G. Moore
Published By: Wolters Kluwer / Lippincott Williams & Wilkins 2011

2011
Chapter Title: Management of Ovarian Cysts and Adnexal Masses
Book Title: Precis Gynecology
Author List: Richard G. Moore and Shannon MacLaughlan
Published By: Precis: Gynecology 2011

2011
Chapter Title: Forward
Book Title: Clinical Obstetrics and Gynecology,
Author List: James W. Orr and Richard G. Moore
Published By: Wolters Kluwer / Lippincott Williams & Wilkins 2011

VIEW ALL PUBLICATIONS